Why Biohaven Pharmaceutical Stock Is Tanking Today
Shares of Biohaven Pharmaceutical Holding Co. (NYSE: BHVN) dropped by nearly 13% in pre-market action Tuesday morning. The drugmaker's shares are sinking following the release of disappointing phase 2/3 clinical trial results for its experimental Alzheimer's disease drug known as troriluzole.
Specifically, the company announced yesterday that troriluzole failed to beat out placebo at the 48-week mark in patients with mild to moderate Alzheimer's disease on two measures of cognitive decline: the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 and the Clinical Dementia Rating Scale Sum of Boxes.
Image source: Getty Images.
Source Fool.com
